Ibrance (palbociclib) 125 mg capsules, 21 capsules (Pfizer) Ibrance is indicated for the treatment of breast cancer. Targeted cancer therapy. Delivery from Europe and elsewhere within 4-5 days, payment upon receipt. Order by calling +380996042415.
Delivery methods
- EMC post
Delivery time
- 7-10 days
Payment methods
- Payment to Revolut card
-
Indications
- Ibrance is indicated for the treatment of hormone receptor-positive (HR-positive), human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer in combination with:
- Letrozole as initial hormonal therapy in postmenopausal women;
- Fulvestrant in women with disease progression after endocrine therapy.
- The indication for use in combination with letrozole is approved under accelerated approval based on progression-free survival. Full approval for this indication is contingent on verification and description of clinical benefit in a confirmatory trial.
- Trade Name:Ibrance. Reamplify
- Chemical Name:Palbociclib
- Dosage:125 mg
- Quantity:21
- Form of Issue:Tablets
- Manufacturer:Pfizer
No reviews yet
